The $1.1 Billion RCM Stake: How Bon Secours Mercy Turned Revenue Cycle Into a Balance-Sheet Asset

Bon Secours Mercy Health has received nearly $1.1 billion in cash distributions in 2026 from its minority stake in Ensemble Health Partners — while retaining roughly 41% ownership. Its hospital operations generated $193 million of operating income in the first half. The overlooked lesson isn't simply “outsource RCM.” It is that the revenue cycle can create enterprise value far beyond cost-to-collect.

Sources: Becker's Hospital Review · Ensemble Health Partners · Bon Secours Mercy Health

The Number That Changes the Frame

According to Bon Secours Mercy Health's August financial disclosure, the health system received a $426.6 million distribution in February and a further $670.8 million net cash distribution tied to Ensemble's August recapitalization. That is nearly $1.1 billion of cash from an RCM ownership position in a single year.

Put that beside the core hospital business. Bon Secours Mercy reported $193 million of operating income for the first six months of 2026, at a 2.6% operating margin. The comparison is not apples-to-apples — cash distributions are not operating earnings — but the scale is still extraordinary. A minority stake in the company running revenue cycle operations has become a major source of liquidity for the health system.

This Wasn't Just a Billing Department Spinout

The clean version of the story would be: health system builds billing operation, spins it out, and makes billions. The actual history is more interesting — and more useful.

Ensemble was founded in 2014 by Judson Ivy. Mercy Health acquired the company in 2016 to accelerate its own revenue cycle transformation and Ensemble's growth as a platform serving unaffiliated health systems. After Mercy Health combined with Bon Secours in 2018, the resulting system brought in outside capital to scale Ensemble faster.

In 2019, Bon Secours Mercy sold 51% of Ensemble to Golden Gate Capital for $1.2 billion and remained a commercial partner, board participant, and minority owner. In 2022, a Berkshire Partners and Warburg Pincus investment reduced BSMH's ownership from 48.3% to 41.8% and triggered a separate $200 million cash dividend to the health system.

Now, in 2026, Thoreau has entered as another investor. Berkshire, Warburg, and Bon Secours Mercy all remain invested, and BSMH says it continues to own about 41%.

The Asset Wasn't RCM. It Was RCM + Distribution.

The reason this matters is that hospitals do not create multi-billion-dollar businesses simply by being good at collecting their own accounts receivable. The enterprise value came from turning an internal strategic capability into a repeatable product for other health systems.

Ensemble now manages end-to-end revenue cycle operations for more than 200 hospitals. The platform spans patient access, coding, claims, denial prevention, AR follow-up, and patient financial experience. In the 2022 transaction, Bloomberg reported that Ensemble was valued at more than $5 billion including debt. The 2026 sponsor change shows that private capital still sees significant value in scaled RCM managed services.

Why Private Equity Keeps Coming Back to RCM

The Ensemble story helps explain why revenue cycle continues to attract some of the largest healthcare investors even as AI threatens to compress labor-heavy delivery models.

At scale, end-to-end RCM has several characteristics private equity likes: deeply embedded workflows, long-duration customer relationships, mission-critical revenue impact, significant switching costs, and a large installed labor base that technology can make more productive. AI does not necessarily destroy that model. For scaled platforms with proprietary workflow data and distribution, it can expand margins and deepen the moat.

That is also why the market is bifurcating. Point solutions can be vulnerable to EHR bundling and commoditization. Large managed-service platforms can use AI across thousands of employees, millions of claims, and dozens of health systems — creating an operating leverage story that is difficult for smaller vendors to reproduce.

The More Important Question for Health Systems

Most health system RCM strategy asks one of two questions: Should we keep this in-house? Or should we outsource it?

Ensemble suggests a third question for systems with genuinely differentiated capabilities:

Is there something inside our administrative operating model that other healthcare organizations would pay to use — and that could be worth more as a platform than as an internal department?

That could be revenue cycle. It could be specialty pharmacy, supply chain, analytics, digital access, clinical staffing, or another function where a health system has built something unusually strong. The bar is high. But the value creation can be dramatically larger than the annual savings from another outsourcing RFP.

RCAI Take

The headline is the $1.1 billion. The strategic signal is the retained 41%.

Bon Secours Mercy did not maximize a one-time sale and walk away. Across multiple sponsor transitions, it remained both a major customer and an equity owner. That structure let the health system participate in the value created as Ensemble scaled beyond its original parent.

For revenue cycle leaders, the takeaway is not that the department should become a startup. It is that RCM capability has enterprise value. When the operating model, technology, data, talent, and distribution are strong enough, the revenue cycle stops being just a cost center. It becomes infrastructure — and infrastructure can become an asset.